How Moderna executives are cashing in on COVID-19 vaccine stock speculation

How Moderna executives are cashing in on COVID-19 vaccine stock speculation

By Administrator_India

Capital Sands

Biotech firm Moderna Inc could reap tens of billions of dollars in sales and stock appreciation if it wins the race for a COVID-19 vaccine. If it loses, the early-stage company’s value could crash.

In the meantime, the firm’s chief executive is pocketing millions of dollars every month by selling shares that have tripled in price on news of Moderna’s development progress, a Reuters analysis of corporate filings shows. The sales – by CEO Stéphane Bancel, his childrens’ trust and companies he owns – amount to about $21 million (£17 million) between January 1 and June 26, including $6 million in May.

The company’s chief medical officer, Tal Zaks, has cashed out the majority of his available stock and options, netting over $35 million since January, the filings show.

The lucrative liquidations highlight the unusually powerful incentives for biotech executives to highlight development milestones for drugs that often never get approved or sold, according to interviews with seven executive-compensation experts. Optimistic corporate statements on coronavirus vaccines, they said, could cause investors to overpay for company shares or create false hope among the public and health officials seeking new weapons to fight the pandemic.

Bancel set a fixed schedule for his share sales – known as a 10b5-1 plan – long before the pandemic hit. Such executive share-sale plans are meant to guard against insider trading, avoiding the potential for executives to sell in advance of bad news they know is coming, or to put off selling until after a positive announcement.

Zaks sharply increased the pace of his sales with a new plan he put in place on March 13. That was three days before Moderna announced it had dosed the first human with a vaccine candidate, news that sent its stock price up 24% and signaled that future development milestones might push the shares higher.

The sales give the firm’s executives an unusual opportunity to lock in big profits on what could be fleeting market optimism, said Jesse Fried, a Harvard Law School professor who wrote a book about executive compensation.

Related Posts
India reports 4,194 new COVID-19 cases, 255 deaths from virus in 24 hours
new Covid cases

India reported 4,194 new COVID-19 cases in the last 24 hours taking the total confirmed tally to 4,29,84,261 while active infections continued Read more

ब्रिटेन में 12 साल से कम उम्र के बच्चों को भी लगेगी Covid वैक्सीन, रेगुलेटरी एजेंसी ने दी मंजूरी
कोरोना वायरस (Coronavirus) के नए और अधिक संक्रामक वेरिएंट ओमिक्रॉन (Omicron) के सामने आने के बाद ब्रिटेन में हालात बिगड़ते जा रहे हैं.

कोरोना वायरस (Coronavirus) के नए और अधिक संक्रामक वेरिएंट ओमिक्रॉन (Omicron) के सामने आने के बाद ब्रिटेन में हालात बिगड़ते Read more

COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla
COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla

By Administrator_India Capital Sands Export of COVID-19 vaccines can start in about next two weeks, the Business Standard reported, quoting Serum Read more

Serum, Bharat Biotech vaccines get restricted use approval from DCGI
COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla

By Administrator_India Capital Sands India’s drug regulator on Sunday gave its final approval to the Oxford-AstraZeneca and Bharat Biotech coronavirus vaccines for restricted use Read more

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x